Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

November 23, 2016 7:05 AM EST

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options, lly

Add Your Comment